A framework for the systematic consideration of ethics, equity, feasibility, and acceptability in vaccine program recommendations.
Acceptability
Equity
Ethics
Feasibility
Framework
Vaccine Program
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
10 08 2020
10 08 2020
Historique:
received:
17
01
2020
revised:
15
05
2020
accepted:
17
05
2020
pubmed:
14
6
2020
medline:
28
4
2021
entrez:
14
6
2020
Statut:
ppublish
Résumé
For the successful implementation of population-level recommendations, it is critical to consider the full spectrum of public health science, including clinical and programmatic factors. Current frameworks may identify various factors that should be examined when making evidence-informed vaccine-related recommendations. However, while most immunization guidelines systematically assess clinical factors, such as efficacy and safety of vaccines, there is no published framework outlining how to systematically assess programmatic factors, such as the ethics, equity, feasibility, and acceptability of recommendations. We have addressed this gap with the development of the EEFA (Ethics, Equity Feasibility, Acceptability) Framework, supported by evidence-informed tools, including Ethics Integrated Filters, Equity Matrix, Feasibility Matrix, and an Acceptability Matrix. The Framework and tools are based on five years of environmental scans, systematic reviews and surveys, and refined by expert and stakeholder consultations and feedback. For each programmatic factor, the EEFA Framework summarizes the minimum threshold for consideration and when further in-depth analysis may be required, which aspects of the factor should be considered, how to assess the factor using the supporting evidence-informed tools, and who should be consulted to complete the assessment. Research, particularly in the fields of vaccine acceptability and equity, has validated the utility and comprehensiveness of the tools. The Framework has been successfully used in Canada for clear, timely, transparent vaccine guidance with positive stakeholder feedback on its comprehensiveness, relevance and appropriateness. Applying the EEFA Framework allows for the systematic consideration of the spectrum of public health science without a delay in recommendations, complementing existing decision-making frameworks. This Framework will therefore be useful for advisory groups worldwide to integrate critical factors that could impact the successful and timely implementation of comprehensive, transparent recommendations, and will further the global objective of developing practical and evidence-informed immunization policies.
Identifiants
pubmed: 32532544
pii: S0264-410X(20)30696-4
doi: 10.1016/j.vaccine.2020.05.051
pmc: PMC7283073
pii:
doi:
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5861-5876Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Vaccine. 2010 Apr 19;28 Suppl 1:A58-63
pubmed: 20412999
PLoS Med. 2012;9(10):e1001333
pubmed: 23222917
Clin Infect Dis. 2012 Nov 15;55(10):1320-8
pubmed: 22828595
Can Commun Dis Rep. 2014 Apr 17;40(8):152-153
pubmed: 29769896
Vaccine. 2018 Jan 2;36(1):148-154
pubmed: 29174683
Vaccine. 2005 Mar 31;23(19):2470-6
pubmed: 15752833
PLoS One. 2017 Mar 30;12(3):e0174831
pubmed: 28358870
N Engl J Med. 2015 May 28;372(22):2087-96
pubmed: 25916341
Can Commun Dis Rep. 2009 Jan;35(ACS-1):1-10
pubmed: 19192504
J Infect Dis. 2008 Mar 1;197 Suppl 2:S228-36
pubmed: 18419402
Can Commun Dis Rep. 2014 May 01;40(9):170-171
pubmed: 29769899
N Engl J Med. 2005 Jun 2;352(22):2271-84
pubmed: 15930418
Clin Vaccine Immunol. 2009 May;16(5):646-52
pubmed: 19261769
Vaccine. 2017 Apr 25;35(18):2329-2337
pubmed: 28341112
Vaccine. 2014 Mar 26;32(15):1745-53
pubmed: 24508036
Vaccine. 2017 Dec 15;35(50):6984-6989
pubmed: 29128385
Vaccine. 2020 Jan 29;38(5):1089-1095
pubmed: 31786003
N Engl J Med. 2016 Sep 15;375(11):1019-32
pubmed: 27626517
Health Policy Plan. 2012 May;27 Suppl 2:ii62-76
pubmed: 21733989
Can Commun Dis Rep. 2014 Jan 24;40(2):13-14
pubmed: 29769877
Biosecur Bioterror. 2014 Sep-Oct;12(5):263-73
pubmed: 25254915
Inj Control Saf Promot. 2003 Mar-Jun;10(1-2):11-2
pubmed: 12772480
Health Res Policy Syst. 2018 May 29;16(1):45
pubmed: 29843743